Hans van Houte - 30 Oct 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Nov 2026, 19:47:02 UTC
Prior SEC filing
04 Aug 2026
Next SEC filing
04 Nov 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte
Filing notes and source

Key filing fact

Hans van Houte filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 02 Nov 2026.

Key facts

  • This page summarizes Hans van Houte's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
  • 7 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 02 Nov 2026, 19:47.

Change

  • Previous filing in this sequence was filed on 04 Aug 2026.
  • Current net transaction value: -$74,475.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001817217 Primary reporting owner

van Houte Hans

Relationship
Chief Financial Officer
Address
C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte
Signature date
02 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRIX transaction

Common Stock

Options Exercise

Transaction value
Shares
+3,750
Change %
+9.3%
Price
$0.000000*
Shares after
43,916
Date
30 Oct 2026
Ownership
Direct
NRIX transaction

Common Stock

Options Exercise

Transaction value
Shares
+2,859
Change %
+6.5%
Price
$0.000000*
Shares after
46,775
Date
30 Oct 2026
Ownership
Direct
NRIX transaction

Common Stock

Options Exercise

Transaction value
Shares
+3,573
Change %
+7.6%
Price
$0.000000*
Shares after
50,348
Date
30 Oct 2026
Ownership
Direct
NRIX transaction

Common Stock

Sale

Transaction value
-$74,475
Shares
-2,834
Change %
-5.6%
Price
$26.28
Shares after
47,514
Date
30 Oct 2026
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-3,750
Change %
-33%
Price
$0.000000*
Shares after
7,500
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,750
Exercise price
$0.000000
Footnotes
F3, F4, F5
NRIX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-2,859
Change %
-14%
Price
$0.000000*
Shares after
17,150
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,859
Exercise price
$0.000000
Footnotes
F3, F5, F6
NRIX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-3,573
Change %
-9.1%
Price
$0.000000*
Shares after
35,730
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,573
Exercise price
$0.000000
Footnotes
F3, F5, F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Footnote F2

Represents the weighted average sale price. The lowest price at which shares were sold was $26.135 and the highest price at which shares were sold was $26.42. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Footnote F3

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F4

The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

Footnote F5

RSUs do not expire; they either vest or are canceled prior to the vest date.

Footnote F6

The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

Footnote F7

The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .